The Effect of Heparmin® on Interferon Gamma Levels and Liver Function in Drug Resistance Tuberculosis Patients

Abstract

Objective: This study was conducted to determine the benefits of giving Heparmin® containing Kleinhovia hospita, Curcuma xanthorizza, Nigella sativa, Ophiocephalus striatus, and Andrographis paniculata, to drug resistance tuberculosis patients which aims to minimize the side effects of drug induced liver injury (DILI). Method: This study was a pre-experimental study with a Pre and Post Test Group Design Drug resistance tuberculosis patient treated with a STR regimen plus Heparmin® to determine IFN-γ levels and liver function (aspartate aminotransferase/AST, alanine transaminase/ALT, direct and total bilirubin) before and after treatment at Dr. Soetomo General Academic Hospital, Surabaya and Mohammad Noer Hospital, Pamekasan, Indonesia who met the inclusion and exclusion criteria from February 2020 to February 2021. Result: This study involved 14 drug resistance tuberculosis patients, the most sex was male 10 patients and 4 female patients, mean age 36.5 years, high school education, normal BMI, GeneXpert mycobacterium tuberculosis Detected Medium, without comorbid with primary cases and re-treatment cases had a comparison the same one. There was sputum culture conversion in all subjects in the second month. The mean value of IFN-γ levels before administration of Heparmin® was 90.61±9.11 ng/ml and after administration of Heparmin® 91.11±8.60 ng/ml. The values of AST, ALT, direct and total bilirubin after administration of Heparmin® are still within normal limits. The results of the paired t test and the Wilcoxon test between before and after giving Heparmin® were not significant. Conclusion: There was no difference in IFN-γ levels and liver function before and after giving Heparmin® for 2 months.